Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the
Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) has adopted its final opinion on Iclusig ®
(ponatinib) following the recommendations made by the Pharmacovigilance
Risk Assessment Committee (PRAC) earlier this month.
Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) said today that
normalized Funds From Operations (“FFO”) for the quarter ended September
30, 2014 increased eight percent to $332.8 million, from $307.2 million
for the comparable 2013 period.
- Total Revenues of $707.6 Million - Net Earnings of $9.3 Million; Diluted EPS of $.13 - Non-GAAP Diluted EPS of $.39 Excluding Special Charges
- Progressive Continues to Exceed Expectations - Executing on Strategic Cost Initiatives ATLANTA , Oct.
- Delivers 11% normalized organic revenue growth and $1.05 Adjusted EPS, driven by strong growth in all business segments and regions including 12% normalized organic growth in CAG Diagnostics recurring revenues
- Catalyst® and hematology instrument placements both increased over 30% in US and international markets - Transition to all-direct sales strategy in the US on track for 100% direct order and fulfillment capability in Q4 - Company announces launch of Catalyst One™, the Company's next generation chemistry analyzer, with customer shipments beginning November 3 - Strong business momentum supports increase in 2014 Adjusted EPS guidance to $3.85 to $3.90 and preliminary 2015 outlook for 13% to 14% normalized organic revenue growth and $4.38 to $4.48 Adjusted EPS WESTBROOK, Maine , Oct.
Second Quarter Highlights: Sales improved 5.9% to $147.0 million Gross margin of 32.1% tied for highest level in the Company's history as a public company Operating margin improved to 11.0%, up 220 basis points; 47.3% operating leverage Generated $6.3 million of cash from operations EPS increased 47.2% to $0.53
AMHERST, N.Y., Oct.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.